B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses

Journal of Neuroimmunology

Volumn 291, Issue , 2016, Pages 46-53

  Ireland, Sara J ^a   Guzman, Alyssa A ^a   Frohman, Elliot M ^a   Monson, Nancy L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

B cells; Multiple sclerosis; Th17 cells

Indexed keywords

ADULT; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CYTOKINE; LEUKOCYTE ANTIGEN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ANTIGENS, CD; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; TH17 CELLS;

EID: 84959362172     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.11.022     Document Type: Article

References (45)

1. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007, 8:639-646.
2. Agrawal S., Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J. Clin. Immunol. 2011, 31:89-98.
3. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
4. Appel H., Neure L., Kuhne M., Braun J., Rudwaleit M., Sieper J. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clin. Rheumatol. 2004, 23:435-440.
5. Arbour N., Lapointe R., Saikali P., Mccrea E., Regen T., Antel J.P. A new clinically relevant approach to expand myelin specific T cells. J. Immunol. Methods 2006, 310:53-61.
6. Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006, 116:3252-3257.
7. Baccam M., Woo S.Y., Vinson C., Bishop G.A. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J. Immunol. 2003, 170:3099-3108.
8. Barbosa R.R., Silva S.P., Silva S.L., Melo A.C., Pedro E., Barbosa M.P., Pereira-Santos M.C., Victorino R.M., Sousa A.E. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One 2011, 6.
9. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial 2008, 63:395-400.
10. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., Calabresi P.A., Waubant E., Hauser S.L., Zhang J., Smith C.H. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67:452-461.
11. Barr T.A., Shen P., Brown S., Lampropoulou V., Roch T., Lawrie S., Fan B., O'connor R.A., Anderton S.M., Bar-Or A., Fillatreau S., Gray D. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 2012, 209:1001-1010.
12. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
13. Callahan M.K., Williams K.A., Kivisakk P., Pearce D., Stins M.F., Ransohoff R.M. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J. Neuroimmunol. 2004, 153:150-157.
14. Cosmi L., De Palma R., Santarlasci V., Maggi L., Capone M., Frosali F., Rodolico G., Querci V., Abbate G., Angeli R., Berrino L., Fambrini M., Caproni M., Tonelli F., Lazzeri E., Parronchi P., Liotta F., Maggi E., Romagnani S., Annunziato F. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 2008, 205:1903-1916.
15. Devaux B., Enderlin F., Wallner B., Smilek D.E. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J. Neuroimmunol. 1997, 75:169-173.
16. Foster B., Prussin C., Liu F., Whitmire J.K., Whitton J.L. Detection of intracellular cytokines by flow cytometry. Curr. Protoc. Immunol. 2007, (Chapter 6, Unit 6 24).
17. Gagro A., Servis D., Cepika A.M., Toellner K.M., Grafton G., Taylor D.R., Branica S., Gordon J. Type I cytokine profiles of human naive and memory B lymphocytes: a potential for memory cells to impact polarization. Immunology 2006, 118:66-77.
18. Giunti D., Borsellino G., Benelli R., Marchese M., Capello E., Valle M.T., Pedemonte E., Noonan D., Albini A., Bernardi G., Mancardi G.L., Battistini L., Uccelli A. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J. Leukoc. Biol. 2003, 73:584-590.
19. Harp C.T., Lovett-Racke A.E., Racke M.K., Frohman E.M., Monson N.L. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin. Immunol. 2008, 128:382-391.
20. Harp C.T., Ireland S., Davis L.S., Remington G., Cassidy B., Cravens P.D., Stuve O., Lovett-Racke A.E., Eagar T.N., Greenberg B.M., Racke M.K., Cowell L.G., Karandikar N.J., Frohman E.M., Monson N.L. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 2010, 40:2942-2956.
21. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., Johnson L.L., Swain S.L., Lund F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 2000, 1:475-482.
22. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
23. Ireland S.J., Blazek M., Harp C.T., Greenberg B., Frohman E.M., Davis L.S., Monson N.L. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 2012, 45:400-414.
24. Ireland S.J., Guzman A.A., O'brien D.E., Hughes S., Greenberg B., Flores A., Graves D., Remington G., Frohman E.M., Davis L.S., Monson N.L. The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 2014, 71:1421-1428.
25. Jingwu Z., Medaer R., Hashim G.A., Chin Y., Van Den Berg-Loonen E., Raus J.C. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 1992, 32:330-338.
26. Kappos L., Li D., Calabresi P.A., O'Connor P., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., Hauser S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011.
27. Kerlero De Rosbo N., Hoffman M., Mendel I., Yust I., Kaye J., Bakimer R., Flechter S., Abramsky O., Milo R., Karni A., Ben-Nun A. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 1997, 27:3059-3069.
28. Kinnunen T., Chamberlain N., Morbach H., Choi J., Kim S., Craft J., Mayer L., Cancrini C., Passerini L., Bacchetta R., Ochs H.D., Torgerson T.R., Meffre E. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2013, 121:1595-1603.
29. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122(Pt 11):2089-2100.
30. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
31. Mahnke Y.D., Brodie T.M., Sallusto F., Roederer M., Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 2013, 43:2797-2809.
32. Martinez-Forero I., Garcia-Munoz R., Martinez-Pasamar S., Inoges S., Lopez-Diaz DE CERIO A., Palacios R., Sepulcre J., Moreno B., Gonzalez Z., Fernandez-Diez B., Melero I., Bendandi M., Villoslada P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 2008, 38:576-586.
33. Melton A.C., Melrose J., Alajoki L., Privat S., Cho H., Brown N., Plavec A.M., Nguyen D., Johnston E.D., Yang J., Polokoff M.A., Plavec I., Berg E.L., O'mahony A. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One 2013, 8.
34. Molnarfi N., Schulze-Topphoff U., Weber M.S., Patarroyo J.C., Prod'homme T., Varrin-Doyer M., Shetty A., Linington C., Slavin A.J., Hidalgo J., Jenne D.E., Wekerle H., Sobel R.A., Bernard C.C., Shlomchik M.J., Zamvil S.S. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 2013, 210:2921-2937.
35. Monson N.L., Cravens P., Hussain R., Harp C.T., Cummings M., De Pilar Martin M., Ben L.H., Do J., Lyons J.A., Lovette-Racke A., Cross A.H., Racke M.K., Stuve O., Shlomchik M., Eagar T.N. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 2011, 6.
36. Olsson T., Zhi W.W., Hojeberg B., Kostulas V., Jiang Y.P., Anderson G., Ekre H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 1990, 86:981-985.
37. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., Ebers G.C. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-936. Canadian Collaborative Study, G.
38. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006, 212:28-50.
39. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
40. Smeland E.B., Blomhoff H.K., Funderud S., Shalaby M.R., Espevik T. Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J. Exp. Med. 1989, 170:1463-1468.
41. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
42. Van De Veerdonk F.L., B.L., Marijnissen R.J., Timmermans K., Di Padova F., Koenders M.I., Gutierrez-Roelens I., Durez P., Netea M.G., Van Der Meer J.W., Van Den Berg W.B., Joosten L.A. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011, 63:1507-1516.
43. Weber M.S., Prod'Homme T., Patarroyo J.C., Molnarfi N., Karnezis T., Lehmann-Horn K., Danilenko D.M., Eastham-Anderson J., Slavin A.J., Linington C., Bernard C.C., Martin F., Zamvil S.S. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann. Neurol. 2010, 68:369-383.
44. Yang Y., Weiner J., Liu Y., Smith A.J., Huss D.J., Winger R., Peng H., Cravens P.D., Racke M.K., Lovett-Racke A.E. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J. Exp. Med. 2009, 206:1549-1564.
45. Zhang M., Wang Z., Graner M.W., Yang L., Liao M., Yang Q., Gou J., Zhu Y., Wu C., Liu H., Zhou B., Chen X. B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell. Immunol. 2011, 270:217-223.